Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension

Last updated: November 16, 2016
Sponsor: Novartis
Overall Status: Completed

Phase

3

Condition

Stress

Vascular Diseases

Circulation Disorders

Treatment

N/A

Clinical Study ID

NCT00353912
CVAA489A2402
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 years of age or older.

  • Moderate to severe high blood pressure. This is defined as a systolic pressure (thetop number) greater than or equal to 160 mmHg and less than 200 mmHg.

Exclusion

Exclusion Criteria:

  • History of allergy or hypersensitivity to ARBs, CCBs, thiazide diuretics

  • Inability to stop all prior blood pressure medications safely

  • Systolic BP ≥ 200 mmHg and/or diastolic BP ≥ 120 mmHg

  • Controlled blood pressure (systolic BP < 140 mmHg) taking more than 3 antihypertensivemedications at screening

  • Systolic BP ≥ 140 mmHg and < 180 mmHg taking more than two antihypertensivemedications at screening

  • Systolic BP ≥ 180 mmHg taking more than one antihypertensive medication at screening

  • History of autoimmune diseases

  • History of multiple drug allergies

  • Liver disease

  • Pancreatic injury within 1 year of screening

  • Evidence of kidney impairment or history of dialysis

  • Any surgical or medical condition which might alter the absorption, distribution,metabolism, or excretion of any drug. This could include currently active gastritis,ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction.

  • Women of child-bearing potential (WOCBP), defined as all women physiologically capableof becoming pregnant, would be excluded UNLESS they are post-menopausal, surgicallysterile OR are using acceptable methods of contraception. The use of hormonalcontraceptives is not allowed

  • Pregnant or nursing (lactating) women

  • History of malignancy of any organ system within the past five years

  • Any severe, life-threatening disease within the past five years

  • History of drug or alcohol abuse within the last 2 years.

  • History of stroke, angioplasty, coronary artery bypass graft surgery, heart attack orunstable angina

  • Type 1 diabetes

  • Poorly controlled Type 2 diabetes

  • History of heart failure

  • Arrhythmia

  • Significant valvular heart disease

  • Active gout Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Total Participants: 571
Study Start date:
June 01, 2006
Estimated Completion Date:
April 30, 2007

Connect with a study center

  • Novartis Pharmaceuticals

    E. Hanover, New Jersey 07936
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.